Earnings
Ascendis Pharma Adds Growth-Hormone Group To Combination Trial — Regulatory Feedback Delays The Study
The larger study must establish each drug's contribution as Ascendis pursues benefits beyond height for children with achondroplasia.
Ascendis Pharma (ASND) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
The larger study must establish each drug's contribution as Ascendis pursues benefits beyond height for children with achondroplasia.
Earnings
Product revenue rose 89% as international launches expanded the reach of its hormone replacement treatment.